While AT2 and AT1 receptor expression is significantly elevated in prostate tumor tissue, prostate cancer is one of the few malignancies in which AT2 expression is known to be down-regulated in high-grade tumors2. This evidence concerns the gene AGTR1 and prostate carcinoma.